Nucala® (mepolizumab) – Expanded indication
September 12, 2019 - GlaxoSmithKline announced the FDA approval of Nucala (mepolizumab), add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
Download PDF
